A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf
.
Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation
[article]
2021
bioRxiv
pre-print
New affordable therapeutic protocols for COVID-19 are urgently needed despite the increasing number of effective vaccines and monoclonal antibodies. To this end, there is increasing attention towards computational methods for drug repositioning and de novo drug design. Here, we systematically integrated multiple data-driven computational approaches to perform virtual screening and prioritize candidate drugs for the treatment of COVID-19. From the set of prioritized drugs, we selected a subset
doi:10.1101/2021.04.15.440004
fatcat:jvpshosxgvg4je7ioaatg2um4m